Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for the stock over the next six months [11]. Core Insights - The company reported a revenue of 3.056 billion yuan for 2025, representing a year-on-year growth of 43.9%, with commercial sales revenue increasing by 51.5% [2][3]. - The inclusion of two innovative dual-antibody drugs, Cardunili and Ivorosi, in the national medical insurance directory has significantly boosted sales [2][3]. - The company has expanded its sales team to approximately 1,300 personnel, focusing on oncology and specialty drugs [3]. - Clinical data for core products continues to validate their global competitiveness, with Ivorosi achieving significant results in lung cancer treatment [3]. - The company is advancing its "IO2.0 + ADC2.0" strategy, with new products in the autoimmune metabolism field and ongoing clinical trials for next-generation ADC drugs [4]. Financial Summary - The company expects revenues of 5.161 billion yuan, 7.106 billion yuan, and 8.752 billion yuan for 2026, 2027, and 2028, respectively, with net profits projected at 244 million yuan, 1.111 billion yuan, and 1.569 billion yuan [4][6]. - The EBITDA loss for 2025 was 192 million yuan, a reduction from 241 million yuan in the previous year [2][3]. - The company’s gross margin is expected to improve, reaching 82.0% by 2028 [12].

Core Viewpoint - Sanofi has ceased the supply of its new lipid-lowering drug, Praluent (alirocumab injection), in the Chinese market due to global supply issues and a strategic shift in its cardiovascular market approach [1][4]. Company Summary - Sanofi has officially notified multiple hospitals about the discontinuation of Praluent in China [2]. - Praluent is a PCSK9 inhibitor used for the prevention of cardiovascular events and treatment of primary hypercholesterolemia and mixed dyslipidemia. It was one of the first PCSK9 monoclonal antibodies approved globally, receiving approval in the U.S. in 2015 and entering the Chinese market in 2020 [4]. - The price of Praluent in China was significantly reduced from 1982 RMB to 306 RMB per injection after being included in the national medical insurance [4]. - Despite the withdrawal of Praluent, Sanofi plans to fill the gap in its cardiovascular pipeline by acquiring exclusive rights to Aficamten, a new cardiac myosin inhibitor, in Greater China, and has also secured rights to another investigational drug, Plerixafor [4][5]. Industry Summary - There are currently seven approved PCSK9-targeted products in China, including three from multinational companies and four from domestic firms. The other products include those from Amgen, Novartis, and Innovent Biologics [7]. - Amgen's Repatha (evolocumab) and Innovent's Xinbile (torcetrapib) are among the alternatives available to patients following Praluent's exit [7]. - Sanofi's recent financial report indicated a revenue of 10 billion euros (approximately 11.4 billion USD) for Q2, with a 10.1% growth, and a total revenue of 19.889 billion euros (approximately 22.8 billion USD) for the first half of the year, reflecting a 9.9% increase [8].